Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 544 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resected Stage Clear all
Completed Phase 1 Interventional

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

NCT01606345
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Valrubicin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 21, 2026, 10:10 PM EDT
Terminated Phase 1 Interventional

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

NCT02714374
View directory record Official record
Conditions
Solid Organ Cancers
Interventions
GL-ONC1
Biological
Lead sponsor
Andrew Lowy
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 21, 2026, 10:10 PM EDT
Not listed Phase 2 Interventional

Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer

NCT00024271
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
recombinant interferon gamma, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, mitomycin C, conventional surgery, hyperthermia treatment, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 21, 2026, 10:10 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers

NCT06554158
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 21, 2026, 10:10 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)

NCT03224182
View directory record Official record
Conditions
Bladder Cancer
Interventions
Qapzola, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 89 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery

NCT01372774
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
stereotactic radiosurgery, whole-brain radiation therapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
37
States / cities
Burlingame, California • Los Angeles, California • Newark, Delaware + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

NCT03522298
View directory record Official record
Conditions
Glioblastoma, Adult
Interventions
Paxalisib (GDC-0084)
Drug
Lead sponsor
Kazia Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

NCT01150045
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
826
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 21, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional Results available

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

NCT03363659
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Disulfiram, Copper gluconate, Temozolomide
Drug · Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 21, 2026, 10:10 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755
View directory record Official record
Conditions
Stage II-IIIB Non-small Cell Lung Carcinoma
Interventions
Osimertinib 80 mg/40 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Santa Rosa, California • Las Vegas, Nevada • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 21, 2026, 10:10 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

NCT03383458
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
Nivolumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
28
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 10:10 PM EDT
Not listed Phase 1 Interventional

Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®

NCT05363826
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain, Glioma, Sarcomatous
Interventions
photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)
Combination Product
Lead sponsor
Photolitec LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Early Phase 1 Interventional

LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

NCT04391595
View directory record Official record
Conditions
Glioblastoma, GBM, Glioma
Interventions
Abemaciclib, LY3214996
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional

Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer

NCT00003831
View directory record Official record
Conditions
Lung Cancer
Interventions
conventional surgery
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
70
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 21, 2026, 10:10 PM EDT
Not yet recruiting Not applicable Interventional

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

NCT07254650
View directory record Official record
Conditions
Lung Cancer (Diagnosis)
Interventions
Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional

Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed

NCT00040898
View directory record Official record
Conditions
Liver Cancer
Interventions
Sho-saiko-to
Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

NCT00621049
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Docetaxel/Carboplatin/Bevacizumab/Erlotinib, Docetaxel/Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
26
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas

NCT00084383
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
GVAX pancreatic cancer vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 21, 2026, 10:10 PM EDT
Withdrawn Phase 2 Interventional

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

NCT00408772
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation
Biological · Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 21, 2026, 10:10 PM EDT
Not listed Phase 1 Interventional

Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)

NCT02210494
View directory record Official record
Conditions
EMR Ulcer
Interventions
Secretrol
Drug
Lead sponsor
Effexus Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Indomethacin Capsules to Treat Dental Pain

NCT00964431
View directory record Official record
Conditions
Dental Pain
Interventions
Celecoxib 400 mg, Placebo, Indomethacin Test (lower dose), Indomethacin Test (upper dose)
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer

NCT00726622
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Open laparotomy and rectal resection, Laparoscopic-assisted rectal resection
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
35
States / cities
Scottsdale, Arizona • Concord, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 21, 2026, 10:10 PM EDT
Recruiting Phase 2 Interventional

A Study of LY4515100 in Participants With Pain Following Third Molar Removal

NCT07511816
View directory record Official record
Conditions
Acute Pain, Molar, Molar, Third, Surgery, Oral
Interventions
LY4515100, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 40 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 10:10 PM EDT